Skip to content

Psilocybin and psychedelic-assisted therapy: all studies

Page 7 of 25: studies 61 to 70 of 248, newest first. Back to the psilocybin and psychedelic-assisted therapy overview

Research

Psilocybin-assisted psychotherapy as a rapid-acting treatment for cancer-related depression and anxiety: Evidence from a network meta-analysis

The International Journal of Psychiatry in Medicine April 25, 2025 Damian Swieczkowski, Aleksander Kwaśny, Michal Pruc et al. 4 citations

Objective To evaluate psilocybin's efficacy in reducing depressive and anxiety symptoms in cancer patients based on randomized controlled trials (RCTs). Methods This systematic review and network meta-analysis (NMA) followed PRISMA and Cochrane Handbook guidelines. PubMed, Embase and Cochrane Library data up to July 2024 were analyzed. Two RCTs met the inclusion criteria. Changes in Beck...

DOI: 10.1177/00912174251337572 (opens in new tab) Major depressive disorder Palliative medicine Palliative psychiatry Rapid-acting antidepressants +5

Evaluating the effectiveness of psilocybin in alleviating distress among cancer patients: A systematic review.

Palliative & Supportive Care April 22, 2025 Maria I Lapid, Sandeep R Pagali, Andrea L Randall et al. 9 citations

Psychological and existential distress is prevalent among patients with life-threatening cancer, significantly impacting their quality of life. Psilocybin-assisted therapy has shown promise in alleviating these symptoms. This systematic review aims to synthesize the evidence on the efficacy and safety of psilocybin in reducing cancer-related distress. We searched MEDLINE, APA PsycINFO, Cochrane...

Roadmap for Equitable Access and Responsible Use of Psilocybin-Assisted Psychotherapy in Palliative Care

Palliative Medicine Reports April 17, 2025 Michel Dorval, Sue-Ling Chang, Houman Farzin et al. 3 citations

Psilocybin-assisted psychotherapy represents a promising addition to palliative care interventions, potentially improving quality of life by addressing existential distress. Despite its safety and effectiveness, this therapy remains limited in Canada, underscoring the need for improved access to ease suffering from life-threatening illnesses. However, important questions remain regarding how to...

DOI: 10.1089/pmr.2024.0108 (opens in new tab) Psilocybin Palliative care Psychotherapist Hallucinogen

Exploring the potential of psychedelic-assisted psychotherapy for moral injury: A scoping review.

Progress in neuro-psychopharmacology & biological psychiatry April 2, 2025 Viktoriia Kurkova, Olga Winkler, Andrew J. Greenshaw et al.

This scoping review addresses the need to comprehensively explore the potential of psychedelic-assisted psychotherapy (PAP) to facilitate recovery from moral injury. Moral injury (MI), characterized by profound psychological distress arising from morally challenging experiences, has garnered increased attention as a complex mental health concern with significant functional sequelae, especially...

Comparative Efficacy and Functional Outcomes of Psychedelic-Assisted Therapies in Treatment-Resistant Depression: A Systematic Review of Recent Clinical Trials.

Cureus April 1, 2025 Ciara Mimms, Kassandra Sotelo, Abdul Saboor Khaliq 1 citation

This systematic review explores the comparative efficacy and functional outcomes of psychedelic-assisted therapies in the management of treatment-resistant depression (TRD). Following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, a comprehensive literature search was conducted across PubMed, Scopus, and Web of Science for randomized controlled...

Comparing Antidepressant Effects of Psilocybin-Assisted Psychotherapy in Individuals That Were Unmedicated at Initial Screening Versus Individuals Discontinuing Medications for Study Participation: Comparaison des effets antidépresseurs de la psychothérapie assistée par la psilocybine (PAP) chez les personnes non médicamentées à la sélection initiale et les personnes ayant arrêté les médicaments pour participer à l’étude

The Canadian Journal of Psychiatry March 25, 2025 Noah Chisamore, Erica Kaczmarek, Zoe Doyle et al. 1 citation

Objective: To compare changes in depression, anxiety, and suicidality symptoms after a single 25 mg oral dose of psilocybin between treatment-resistant depression participants not on antidepressants at screening to participants that discontinued antidepressant medications leading up to receiving psilocybin-assisted psychotherapy (PAP). Methods: Participants (n = 27) received at least one 25 mg...

DOI: 10.1177/07067437251328316 (opens in new tab) Treatment-resistant depression Depressive disorders Mood disorders Psilocybin-assisted psychotherapy +4

A systematic review of participant diversity in psychedelic-assisted psychotherapy trials.

Psychiatry Research March 1, 2025 Stephanie L. Haft, Amanda E. Downey, Marissa Raymond-Flesch et al. 22 citations

A lack of diverse and representative participant samples in mental health intervention research perpetuates mental health disparities. This issue has become a salient concern in studies of psychedelic-assisted psychotherapy (PAT), which is emerging as a promising mental health intervention. This systematic review evaluates the reporting, representation, and analysis of participant...

DOI: 10.1016/j.psychres.2025.116359 (opens in new tab) Full text (opens in new tab) Psychedelic research MDMA Therapy Systematic review Clinical diversity +2

Psilocybin-assisted psychotherapy for Parkinson's disease without depression: A case-report.

Journal of Parkinson's disease March 1, 2025 Vanessa Fleury, Emilie Tomkova, Sabina Catalano Chiuvé et al. 3 citations

BackgroundPsychedelic assisted psychotherapy (PAP) can improve treatment-resistant depression. Its usefulness in Parkinson's disease (PD) is unknown. PD patients may have problems adjusting to their chronic progressive neurological disease. A change from emotional avoidance to acceptance has been reported following psilocybin administration in patients with treatment-resistant...

DOI: 10.1177/1877718x241312604 (opens in new tab) Full text (opens in new tab) Psilocybin therapy Parkinsons treatment Mental health outcomes Patient resilience +4

Prolonged adverse effects from repeated psilocybin use in an underground psychedelic therapy training program: a case report

BMC Psychiatry February 28, 2025 John Perna, Justin Trop, Roman Palitsky et al. 15 citations

This case highlights the tensions between legal and underground psychedelic use within psychedelic therapy training programs, psychiatry and neo-shamanism, and the use of psychiatric interventions (i.e., ECT) and energy medicine to address prolonged adverse effects from psychedelics. Clinicians should be aware of these potential conflicts between psychiatric conceptualizations of PAEs and...

DOI: 10.1186/s12888-024-06303-z (opens in new tab) Psilocybin Hallucinogen Adverse effect Psychotherapist +1

Esse quam Videre: Critical Reflections on the Use of Psilocybin as an Adjuvant in Psychedelic-Assisted Psychotherapy

Polymatheia. February 15, 2025 Fábio Nogueira Pereira, Ana Carina Rothechedl Cavalieri, João Paulo Crespo Ferreira et al.

The ethical and technical challenges of recent research with psychedelics and the attempt to regulate them as a health technology open a new horizon for reflections on scientific development and questions about how we experience spiritual and non-ordinary experiences of consciousness and relate to nature. We understand that Psychology needs to resort to psychedelic philosophy and the knowledge...